The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers

Steiner-Monard, Viviane
Kamaka, Kassim
Karoui, Olfa
Roethlisberger, Samuel
Audran, Régine
Daubenberger, Claudia
Fayet-Mello, Aurélie
Erdmann-Voisin, Aude
Felger, Ingrid
Geiger, Kristina
Govender, Lerisa
Houard, Sophie
Huber, Eric
Mayor, Carole
Mkindi, Catherine
Portevin, Damien
Rusch, Sebastian
Schmidlin, Sandro
Tiendrebeogo, Regis W
Theisen, Michael
Thierry, Anne-Christine
Vallotton, Laure
Corradin, Giampietro
Leroy, Odile
Abdulla, Salim
Shekalaghe, Seif
Genton, Blaise
Spertini, François
Jongo, Said A

Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Ifakara Health Institute, Bagamoyo, Tanzania
Swiss Tropical and Public Health Institute, Basel
Clinical Trial Unit, CHUV, Lausanne
Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
European Vaccine Initiative, Heidelberg, Germany
Department for Congenital Disorders, Statens Serum Institut, Denmark
Centre for Medical Parasitology, University of Copenhagen, Denmark
Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark
Policlinique médicale universitaire, Lausanne, Switzerland
Infectious Disease Service, CHUV, Lausanne, Switzerland

Correspondence: F. Spertin, Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland ([email protected]).

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Received January 19, 2018

Accepted June 25, 2018

Online date: June 26, 2018

Clinical Infectious Diseases 68(3):p 466-474, February 01, 2019. | DOI: 10.1093/cid/ciy514